← Back to Search

Growth Hormone Therapy

Navepegritide for Achondroplasia

Phase 2
Recruiting
Research Sponsored by Ascendis Pharma A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks

Summary

"This trial will test the safety and effectiveness of a new medication called Navepegritide in infants under 2 years old with a specific genetic condition. The medication will be given once a week

Who is the study for?
This trial is for infants under 2 years with achondroplasia, a form of dwarfism. Parents must consent and be able to give weekly shots at home. Babies up to 1 year old need daily Vitamin D; older ones with low levels must start supplements before joining.
What is being tested?
The trial tests Navepegritide (TransCon CNP) against a placebo in babies with achondroplasia. It's given as a shot once a week for a year. The goal is to see if it's safe and works better than no treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To evaluate the effect of Navepegritide on growth
To evaluate the safety and tolerability of Navepegritide

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NavepegritideExperimental Treatment1 Intervention
Once weekly double-blinded treatment with SC injection of 100 µg/kg of Navepegritide for 52 weeks
Group II: Placebo for NavepegritidePlacebo Group1 Intervention
Once weekly double-blinded treatment with SC injection of 100 µg/kg of Placebo for Navepegritide for 52 weeks

Find a Location

Who is running the clinical trial?

Ascendis Pharma A/SLead Sponsor
14 Previous Clinical Trials
1,688 Total Patients Enrolled
4 Trials studying Achondroplasia
365 Patients Enrolled for Achondroplasia
Ascendis Pharma Growth Disorders A/SLead Sponsor
3 Previous Clinical Trials
246 Total Patients Enrolled
3 Trials studying Achondroplasia
246 Patients Enrolled for Achondroplasia
~40 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top